190 related articles for article (PubMed ID: 30548257)
21. Bendamustine-rituximab in mantle cell lymphoma.
Lipsky A; Martin P
Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
[No Abstract] [Full Text] [Related]
22. Long survival in patients with Waldenström macroglobulinaemia diagnosed at a young age.
Babwah A; Gustine J; Meid K; Dubeau T; Xu L; Yang G; Hunter ZR; Treon SP; Castillo JJ
Br J Haematol; 2019 May; 185(4):799-802. PubMed ID: 30407630
[No Abstract] [Full Text] [Related]
23. [Therapy of Waldenström´s macroglobulinaemia in the year 2014].
Adam Z; Krejčí M; Pour L; Ševčíková E
Vnitr Lek; 2014 Feb; 60(2):139-57. PubMed ID: 24754419
[TBL] [Abstract][Full Text] [Related]
24. Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenström macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination.
Pilorge S; Park S; Dreyfus F; Bouscary D; Tamburini J
Leuk Lymphoma; 2010 Dec; 51(12):2288-90. PubMed ID: 20929331
[No Abstract] [Full Text] [Related]
25. Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
Durot E; Tomowiak C; Michallet AS; Dupuis J; Hivert B; Leprêtre S; Toussaint E; Godet S; Merabet F; Van Den Neste E; Ivanoff S; Roussel X; Zini JM; Regny C; Lemal R; Sutton L; Perrot A; Le Dû K; Kanagaratnam L; Morel P; Leblond V; Delmer A
Br J Haematol; 2017 Nov; 179(3):439-448. PubMed ID: 28770576
[TBL] [Abstract][Full Text] [Related]
26. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.
Cheah CY; Nastoupil LJ; McLaughlin P; Fanale MA; Neelapu SS; Fayad LE; Hagemeister FB; Fowler NH
Br J Haematol; 2016 Nov; 175(3):531-533. PubMed ID: 26683805
[No Abstract] [Full Text] [Related]
27. Rituximab intolerance in patients with Waldenström macroglobulinaemia.
Castillo JJ; Kanan S; Meid K; Manning R; Hunter ZR; Treon SP
Br J Haematol; 2016 Aug; 174(4):645-8. PubMed ID: 26523929
[No Abstract] [Full Text] [Related]
28. Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia.
Olszewski AJ; Chen C; Gutman R; Treon SP; Castillo JJ
Br J Haematol; 2017 Oct; 179(1):106-115. PubMed ID: 28677830
[TBL] [Abstract][Full Text] [Related]
29. Waldenström macroglobulinaemia and intestinal lymphangiectasia.
Cooke RE; Kalnins RM; Ho WK
Br J Haematol; 2014 Nov; 167(3):292. PubMed ID: 25039993
[No Abstract] [Full Text] [Related]
30. Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study.
Yamasaki S; Matsushima T; Minami M; Kadowaki M; Takase K; Iwasaki H
Ann Hematol; 2022 Jan; 101(1):209-211. PubMed ID: 33392703
[No Abstract] [Full Text] [Related]
31. Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline.
Pratt G; El-Sharkawi D; Kothari J; D'Sa S; Auer R; McCarthy H; Krishna R; Miles O; Kyriakou C; Owen R
Br J Haematol; 2022 Apr; 197(2):171-187. PubMed ID: 35020191
[TBL] [Abstract][Full Text] [Related]
32. A case of Waldenstrom Macroglobulinemia in which intermittent one-day administration cycles of bendamustine were effective for alleviation of nausea and maintenance of remission.
Sekiguchi Y; Wakabayashi M; Takizawa H; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
J Clin Exp Hematop; 2017 Oct; 57(2):79-81. PubMed ID: 28883220
[No Abstract] [Full Text] [Related]
33. Evidence of bendamustine plus rituximab for old and frail patients with aggressive B-cell lymphoma.
Schalk E; Jentsch-Ullrich K
Ann Hematol; 2023 Jun; 102(6):1617-1620. PubMed ID: 36928308
[No Abstract] [Full Text] [Related]
34. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
[TBL] [Abstract][Full Text] [Related]
35. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia.
Castillo JJ; Advani RH; Branagan AR; Buske C; Dimopoulos MA; D'Sa S; Kersten MJ; Leblond V; Minnema MC; Owen RG; Palomba ML; Talaulikar D; Tedeschi A; Trotman J; Varettoni M; Vos JM; Treon SP; Kastritis E
Lancet Haematol; 2020 Nov; 7(11):e827-e837. PubMed ID: 33091356
[TBL] [Abstract][Full Text] [Related]
36. [Waldenström macroglobulinaemia].
Simon L; Leblond V
Rev Prat; 2018 Sep; 68(7):797-802. PubMed ID: 30869336
[TBL] [Abstract][Full Text] [Related]
37. [Osteonecrosis developing after rituximab-containing chemotherapy for Waldenström macroglobulinemia].
Nakamura F; Hirai R; Higo T; Togano T; Sekine R
Rinsho Ketsueki; 2018; 59(3):305-309. PubMed ID: 29618689
[TBL] [Abstract][Full Text] [Related]
38. A Promising New Therapy of Oral Ixazomib Without Rituximab for Waldenstrom Macroglobulinemia.
Ma W; Zhao J; Zhang L
Turk J Haematol; 2021 Feb; 38(1):87-89. PubMed ID: 33121225
[No Abstract] [Full Text] [Related]
39. Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance.
Ribes D; Hachem HEL; Oberic L; Vergez F; Delas A; Belliere J; Protin C; Kamar N; Ferrandiz I; Tavitian S; Laurent C; Huart A; Chauveau D; Ysebaert L; Faguer S
Am J Hematol; 2018 Mar; 93(3):356-362. PubMed ID: 29168251
[TBL] [Abstract][Full Text] [Related]
40. Leukaemia cutis after starting bendamustine: cause or coincidence?
Mawri S; Nabi S; Jallad B; Won J
BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26392439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]